EUVIMEDEUVIMED entdecken
Crossref

Variations in Patterns of Prescribing Durvalumab in Stage III Lung Cancer: A Survey of Australian Medical Oncologists

Udit Nindra, Victoria Bray, Deme Karikios, Mohsen Shafiei, Shalini Subramaniam, Pei Ding, Steven Kao, Abhijit Pal

Oncology · 2024

DOI: 10.1159/000535855 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology, 2024. Verfasst von Udit Nindra und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Liverpool Hospital, Liverpool, New South Wales, Australia. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Antibodies, Monoclonal, Practice Patterns, Physicians'. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Local Australian guidelines for the optimal management of stage III unresectable non-small cell lung cancer (NSCLC) are lacking. The American Society of Clinical Oncology (ASCO) guidelines recommend consolidation durvalumab for all patients with unresectable stage III NSCLC, irrespective of their PD-L1 expression or driver mutation status. The European Society of Medical Oncology (ESMO) differs, with consolidation durvalumab only recommended in those patients whose tumours express PD-L1.

Methods

Due to differing global guidelines, we conducted an Australia and New Zealand wide survey of medical oncologists specialising in thoracic cancer to determine the variations in patterns of prescribing durvalumab in stage III unresectable NSCLC. This survey was done electronically and sponsored by the Thoracic Oncology Group of Australia (TOGA).

Results

Thirty-two medical oncologists completed the survey. In patients with EGFR-mutated stage III unresectable NSCLC, 6% of respondents stated that they prescribed durvalumab for all patients, while an additional 6% strongly recommended treatment. Forty-four percent suggested little benefit of consolidation durvalumab in this cohort, with an additional 19% advocating for observation only. In patients with PD-L1 negative (0%) stage III unresectable NSCLC, 13% of respondents prescribed durvalumab for all patients, while an additional 56% strongly recommended treatment. Interestingly, 18%, 10%, and 10% of prescribers discussed self-funded oral tyrosine kinase inhibitor therapy in patients with EGFR, ALK, or ROS-1-mutated NSCLC respectively as a substitute for consolidation durvalumab.

Conclusion

Overall, the clinical practice of Australian and New Zealand Medical Oncologists is variable, but remains consistent with either the ASCO or ESMO guidelines. Local practice guidelines are required to ensure consistency in prescribing patterns across Australia, as well as providing evidence for self-funded treatments outside standard of care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCarcinoma, Non-Small-Cell LungAntibodies, MonoclonalPractice Patterns, Physicians'OncologistsNeoplasm StagingHumansAustraliaSurveys and QuestionnairesAntineoplastic Agents, ImmunologicalNew Zealand

Stichwörter der Autor:innen

DurvalumabGuidelinesLung cancerOncogeneStage III

Substanzen

durvalumabAntibodies, MonoclonalAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Medical Oncology, Liverpool Hospital, Liverpool, New South Wales, Australia.
  • Department of Medical Oncology, Nepean Hospital, Nepean, New South Wales, Australia.
  • Department of Medical Oncology, Bankstown-Lidcombe Hospital, Bankstown, New South Wales, Australia.
  • Department of Medical Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
  • Department of Medical Oncology, Sydney, New South Wales, Australia.

Zitieren

APA

Nindra, U., Bray, V., Karikios, D., Shafiei, M., Subramaniam, S., Ding, P., Kao, S., & Pal, A. (2024). Variations in Patterns of Prescribing Durvalumab in Stage III Lung Cancer: A Survey of Australian Medical Oncologists. Oncology. https://doi.org/10.1159/000535855

Vancouver

Nindra U, Bray V, Karikios D, Shafiei M, Subramaniam S, Ding P, et al. Variations in Patterns of Prescribing Durvalumab in Stage III Lung Cancer: A Survey of Australian Medical Oncologists. Oncology. 2024. doi:10.1159/000535855

BibTeX
@article{Nindra2024,
  author = {Nindra, Udit and Bray, Victoria and Karikios, Deme and Shafiei, Mohsen and Subramaniam, Shalini and Ding, Pei and Kao, Steven and Pal, Abhijit},
  title = {Variations in Patterns of Prescribing Durvalumab in Stage III Lung Cancer: A Survey of Australian Medical Oncologists},
  journal = {Oncology},
  year = {2024},
  doi = {10.1159/000535855}
}
Kostenlos starten →